The partnership links real-world product adoption analytics with commercial modelling to assist companies in making clinical development, investment, and commercialisation choices.
The companies will combine their respective analytical tools to generate market projections based on customer behaviour rather than standard assumptions.
Conventional industry forecasts frequently depend on clinical profiles, total market scale, and expected market share.
The joint initiative instead evaluates how interactions between healthcare providers, payers, and patients drive uptake, helping companies identify commercial risks before finalising major development decisions.
Litmys managing partner Harris Kaplan said: “Approval does not equal adoption, and a forecast is only as good as the assumptions behind it. Our work focuses on understanding what will actually drive physicians, payers, and patients to embrace a new product.
“Combining that perspective with PharmaACE’s sophisticated forecasting and analytics capabilities allows us to connect the drivers of adoption more directly to commercial expectations and help clients make better decisions while they still have time to influence the outcome.”
Litmys uses its Realistic Assessment of Market Potential (RAMPx) methodology to assess product advantages, uptake barriers, and stakeholder willingness to alter current behaviours.
PharmaACE then applies forecasting models, commercial analytics, and consulting expertise to translate these findings into market projections.
Together, the firms intend to offer complementary services throughout the product lifecycle, from clinical development through to launch, while establishing an assessment framework to evaluate assets and allocate resources across international portfolios.
Litmys is headquartered in Santa Fe, New Mexico, US, with an additional site in Minneapolis, Minnesota focusing on commercial readiness analytics and development risk assessment for medicines and medical devices.
Established in 2013, PharmaACE is based in Princeton, New Jersey, and maintains offices in Canada, Germany, India, and Portugal.
The consultancy provides analytics, forecasting, and advisory services across therapy areas including cardiometabolic conditions, central nervous system disorders, immunology, oncology, and rare diseases.